4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Biotechnology

Healthcare
$10.46 +1.70%

+$0.16 today

Market cap
$577.85M
Beta
2.76
P/E (TTM)
-4.0
EPS (TTM)
-$2.36
52W Low $3.68High $12.34

Volume 0.68M

Average 0.77M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$109.08M

FY 2025 · Annual

Investing Cash Flow

-$92.97M

FY 2025 · Annual

Financing Cash Flow

$112.96M

FY 2025 · Annual

-66.5% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Depreciation & Amortization3.02M3.88M5.75M6.71M7.63M
Deferred Income Tax00000
Stock-Based Compensation13.8M17.12M19.67M26.12M22.02M
Change in Working Capital(15.53M)(1.34M)630K537K6.17M
Accounts Receivables1.44M47K000
Inventory(4.54M)0000
Accounts Payables2.29M(1.64M)896K871K6.77M
Other Working Capital(14.72M)255K(266K)(334K)(601K)
Other Non-Cash Items898K1.14M(999K)(7.08M)(4.79M)
Operating Cash Flow(69.13M)(86.69M)(75.79M)(134.59M)(109.08M)
Capital Expenditures(9.11M)(11.54M)(2.77M)(3.79M)(536K)
Acquisitions (Net)9.11M0000
Purchases of Investments(168.57M)(153.31M)(54.8M)(467.65M)(442.82M)
Sales of Investments5M147.8M173.29M169M350.38M
Other Investing Activities(9.11M)0173.29M00
Investing Cash Flow(172.68M)(17.05M)115.72M(302.44M)(92.97M)
Debt Repayment00000
Common Stock Issued114.3M3.09M148.34M331.41M112.96M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.79M08.49M5.84M0
Financing Cash Flow118.09M3.09M156.83M337.25M112.96M
Effect of Forex Changes00000
Net Change in Cash(123.73M)(100.65M)196.76M(99.77M)(89.1M)
Free Cash Flow(78.24M)(98.22M)(78.56M)(138.37M)(109.08M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$140.1M
+ D&A$7.6M
+ Stock-Based Comp$22.0M
+ Deferred Tax$0
+ Working Capital$6.2M
- Other Non-Cash-$4.8M
= Operating Cash Flow-$109.1M
- Capex-$536.0K
= Free Cash Flow-$109.1M

Analysis

FY2025 free cash flow is -$109.1M. FCF conversion is 77.9% of net income. Operating cash flow was -$109.1M, with capex of -$536.0K. The largest bridge item is Stock-Based Comp at $22.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
SC 13GSC 13G filingNov 10, 2026
4Statement of changes in beneficial ownershipOct 20, 2026
4Statement of changes in beneficial ownershipOct 7, 2026

Does FDMT generate free cash flow?

4D Molecular Therapeutics, Inc. (FDMT) generated -$109.08M of free cash flow in fiscal 2025.

How much operating cash flow does FDMT produce?

Operating cash flow was -$109.08M, before capital expenditures of $536,000.00.